Benefit-Risk Considerations of Cefiderocol in Clinical Practice
Study authors discuss the uncertainties and challenges in the interpretation of the CREDIBLE-CR trial and benefit-risk considerations for the use of cefiderocol in clinical practice.
Study authors discuss the uncertainties and challenges in the interpretation of the CREDIBLE-CR trial and benefit-risk considerations for the use of cefiderocol in clinical practice.
Researchers tested a new decision support tool to optimize antibiotic prescribing for uncomplicated urinary tract infection.
Study findings suggest that oral β-lactam antibiotics as step-down treatment following treatment with parenteral antibiotics may treat bacteremia from a urinary source when fluoroquinolones or trimethoprim-sulfamethoxazole use is limited by adverse effects or resistance.
Research authors assessed the safety and efficacy of intravesical bacteriophage therapy compared to placebo and current standard of care for the treatment of urinary tract infection in patients undergoing transurethral resection of the prostate.
Risk for cardiac events higher with azithromycin versus amoxicillin in those using QT-prolonging drugs.
From February to April 2020, drop >20% observed for all primary admission diagnoses.
The aim of the study was to use real-world data to compare the risk of cardiac events in new users of azithromycin vs amoxicillin.
The observational study aimed to determine the association between fluoroquinolone use and the risk of aortic aneurysm or aortic dissection while taking into account potential confounding.
Investigators sought to determine whether a new protocol for urine sampling and testing lowers rates of catheter-associated urinary tract infections.
New study is the first focused analysis of bacterial diversity in the urogenital tract of postmenopausal women, according to investigators.